Drug Type Fc fusion protein |
Synonyms 重组抗人EGFR抗体/IL-10双特异Fc融合蛋白 |
Target |
Action antagonists, stimulants |
Mechanism EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists), IL-10R stimulants(Interleukin 10 receptor stimulants) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseIND Approval |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Malignant ascites | IND Approval | China | 21 Apr 2025 | |
Malignant Pleural Effusion | IND Approval | China | 21 Apr 2025 |